Trial
NCT00665652
Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
Celgene Corporation
Condition
Neuropathy
Intervention
Lenalidomide
Why stopped
The study has been suspended for slower than anticipated enrollment to date.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-09-11